Zepbound vs Wegovy: which weekly weight-loss injection fits you in Canada

Zepbound vs Wegovy: the short answer

Zepbound vs Wegovy comes down to a trade: more weight loss on one side, a broader Canadian label on the other. If losing the most weight is the goal, the head-to-head evidence favours Zepbound. If you are a teen, or an adult living with heart disease, Wegovy is the one whose label was written with you in mind².

A quick word on names, since most people first hear about these drugs through Ozempic. In Canada, Ozempic is the semaglutide brand for type 2 diabetes, and Wegovy is the semaglutide brand for weight^5,2.

Lilly does the same thing with tirzepatide, selling it as Mounjaro for diabetes and Zepbound for weight^6,1. Line up the two weight brands and you are really comparing tirzepatide with semaglutide at their full weight-loss doses.

Zepbound and Wegovy compared on weight lost in trials, speed, injection routine, Canadian cash price and approval status

Measure	Zepbound	Wegovy
What it is	GIP and GLP-1 receptor agonist	GLP-1 receptor agonist
Average weight loss	−20.9% in SURMOUNT-1, 72 weeks, 15 mg weekly	−14.9% in STEP 1, 68 weeks, 2.4 mg weekly
Placebo group	3.1%	2.4%
Time to full effect	~17 mo. Full dose after 20 weeks	~16 mo. Full dose after 16 weeks
How you take it	Weekly pen (easy)	Weekly pen (easy)
Cost per month	$314–742 cash, before insurance	$380–507 cash, before insurance
Health Canada	Approved (Zepbound)	Approved
Evidence grade	A: Several positive phase 3 trials (SURMOUNT-1 and -2) and approved for weight management in Canada as Zepbound.	A: Several positive phase 3 trials (STEP 1-3) and approved for weight management in Canada.

Below, we go through what each Canadian label allows, the dose steps, the pens, prices, drug-plan coverage, generics and who should ask for which. If you want the trial tables line by line, our Mounjaro vs Ozempic comparison breaks down the head-to-head study in full.

Zepbound vs Ozempic: why the fair fight is with Wegovy

Zepbound vs Ozempic is the search a lot of Canadians type, but it pits a weight brand against a diabetes brand. Every approval Ozempic has received here since 2018 covers type 2 diabetes, or heart and kidney outcomes in people who have it.

None covers weight management⁵. Zepbound’s label, by contrast, is built around weight and sleep apnea¹.

That label gap shows up in three ways:

• The dose is lower. Semaglutide’s weight trials used 2.4 mg a week, which is the Wegovy maintenance dose. Ozempic’s label goes up to 2 mg, but the 2 mg pen has never been sold here, so the strongest Ozempic pen you can fill delivers 1 mg^3,2. The Wegovy vs Ozempic comparison goes through the rest of that split.
• The prescription is off-label. A doctor can still prescribe Ozempic for weight, but Health Canada never reviewed it for that use⁵.
• The comparison is skewed. When people say “Zepbound beat Ozempic”, they usually mean SURMOUNT-5. The semaglutide group in that trial was dosed up to 2.4 mg, Wegovy’s dose, not Ozempic’s⁴.

So for weight loss, put Zepbound next to Wegovy. If you have type 2 diabetes and are weighing Ozempic, its real rival is Mounjaro, and that is the question our Mounjaro page answers.

One more mix-up comes from US websites. Some say Wegovy now comes as a daily pill.

That pill, oral semaglutide 25 mg, has no Canadian approval and no Drug Identification Number as of November 2026^3,5. In Canada, Wegovy is a weekly injection only.

Which one causes more weight loss?

Zepbound does, by a clear margin. In SURMOUNT-5, 751 adults with obesity but no diabetes took the highest dose of either drug they could tolerate for 72 weeks, and average weight loss was 20.2% on tirzepatide against 13.7% on semaglutide⁴. The study was open-label, so everyone knew which drug they were taking, and Lilly, the company that makes Zepbound, paid for it.

To put the gap in plain terms: for someone who starts at 100 kg, 6.5 percentage points is about 6.5 kg more off the scale on average. That is our arithmetic on the trial averages, not a promise for any one person.

Averages also hide a wide spread. Almost a third of the semaglutide group still lost at least 20% of their body weight⁷, which is about what the average tirzepatide user lost.

Plenty of people do very well on Wegovy. Zepbound simply moves more people into the biggest-loss groups.

What each one is approved for in Canada

Wegovy’s Canadian label is the wider of the two. Both cover weight management in adults, but only Wegovy covers teens, heart-attack risk and a liver disease called MASH. Only Zepbound covers sleep apnea^2,1.

What the Canadian label covers	Zepbound	Wegovy
Adults with a BMI of 30 or more	Yes	Yes
Adults with a lower BMI plus a weight-related condition	BMI 27 to under 30	BMI 27 or more
Teens aged 12 to 17	No	Yes, with conditions
Lowering the risk of a non-fatal heart attack	No	Adults with established heart disease and a BMI of 27 or more
MASH with F2 to F3 liver fibrosis	No	Yes, under a conditional approval
Moderate to severe obstructive sleep apnea	Adults with obesity	No
First approved in Canada	May 13, 2025	November 23, 2021

Sources for the table: the two Canadian product monographs and Health Canada’s Notice of Compliance database^1,2,5.

Heart disease: Wegovy has the outcome trial

Wegovy has a published heart-outcome trial in people without diabetes behind its label, and it is the only one of the two labelled for heart risk here. The SELECT trial enrolled 17,604 adults aged 45 or older who had heart disease, a BMI of 27 or more and no diabetes.

Over an average follow-up of 39.8 months, a heart attack, stroke or death from heart disease happened to 6.5% of people on semaglutide 2.4 mg and 8.0% on placebo⁸. That works out to about a fifth lower risk (a hazard ratio of 0.80).

Health Canada’s wording is narrower than the trial result. The label covers reducing the risk of a non-fatal heart attack in that group².

SELECT also shows the cost of a long trial: 16.6% of people on semaglutide stopped it for good because of side effects, against 8.2% on placebo⁸. Zepbound has no heart-outcome indication in Canada¹.

Sleep apnea: Zepbound has the label

Zepbound is the only weight drug in Canada labelled to treat obstructive sleep apnea, approved for that on June 11, 2026⁵. Two 52-week trials, SURMOUNT-OSA-1 and -2, enrolled 469 adults with obesity and moderate to severe sleep apnea.

Breathing pauses and shallow breaths (measured as events per hour of sleep) fell by 25.3 per hour on Zepbound against 5.3 on placebo in people not using a breathing machine. In people who used one, the drop was 29.3 against 5.5¹.

The label adds a caution: Zepbound does not replace a CPAP machine for people who need one¹. Wegovy’s label mentions sleep apnea only as one of the weight-related conditions that can qualify an adult with a BMI of 27 or more².

Teens: only Wegovy

If you are a parent reading this for a teenager, Wegovy is the only option of the two. Its label covers ages 12 to 17 with a BMI at or above the 95th percentile, a body weight over 60 kg, and too little response to diet and activity alone.

In the STEP TEENS trial, BMI fell 16.1% over 68 weeks on Wegovy, against a 0.6% rise on placebo². Zepbound has not been studied in anyone under 18 and has no pediatric indication in Canada¹.

Pregnancy and birth control

Neither drug may be used during pregnancy^1,2. The timing rules differ, though.

The Zepbound label says to stop at least 1 month before a planned pregnancy, and the Wegovy label says at least 2 months. Each label points to the drug’s long half-life as the reason^1,2.

Birth control pills are the other difference. The Zepbound label tells people on oral hormonal birth control to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase¹.

In Wegovy’s interaction study, semaglutide did not change blood levels of a common birth control pill². If you rely on the pill, ask about this before you pick.

Dose steps in the Canadian monographs

Both drugs start low and climb in steps of four weeks or more, but Wegovy has one target dose and Zepbound has three. We are quoting the Canadian monographs here. Your prescriber sets your schedule.

Dose step	Zepbound	Wegovy
First 4 weeks	2.5 mg a week (a starting dose only)	0.25 mg a week
How it climbs	To 5 mg, then up 2.5 mg at a time after at least 4 weeks on each dose	0.5 mg, 1 mg, 1.7 mg, then 2.4 mg, one step every 4 weeks
Maintenance dose for weight	5, 10 or 15 mg a week	2.4 mg a week, from week 17
Maintenance dose for sleep apnea	10 or 15 mg a week	Not authorized
Highest dose	15 mg a week	2.4 mg a week
If the top dose is too hard to take	No step-down rule; 5 mg and 10 mg are also listed as maintenance doses	Adults may drop to 1.7 mg for up to 4 weeks, then go back up

Doses and steps from the Zepbound and Wegovy product monographs^1,2.

What this means day to day. If you go all the way to 15 mg on Zepbound with no pauses, you reach it at week 21 at the earliest. That is our count from the four-week steps.

Wegovy hits its full dose at week 17². Either label allows a slower climb. Zepbound steps up only after at least 4 weeks on a dose, and the Wegovy label suggests waiting 4 more weeks before a step if the current dose is hard to tolerate^1,2.

The steps also matter for your budget, because Zepbound’s price changes with the pen strength and Wegovy’s does not. More on that in the cost section.

Pens, needles and storage

Both come as multi-dose pens that hold four weekly doses, so one pen lasts about a month^1,2. The real differences are needles and how long a pen can live outside the fridge.

Practical detail	Zepbound KwikPen	Wegovy FlexTouch
Doses per pen	4	4
Needles in the box	No, buy pen needles separately	Yes, 4 disposable needles
Before first use	Fridge, 2°C to 8°C	Fridge, 2°C to 8°C
Out of the fridge	Up to 30 days, not above 30°C	After first use, up to 8 weeks below 30°C or in the fridge
If you miss a dose	Take it within 4 days (96 hours); after that, skip it	Take it if the next dose is at least 2 days (48 hours) away; if not, skip it
Changing your injection day	Allowed if doses stay at least 3 days apart	Allowed if doses stay at least 3 days apart

Pen, storage and missed-dose rules from the two Canadian monographs^1,2.

A few small things trip people up. The Zepbound pen has glass parts, and its label says not to use it if it has been dropped on a hard surface¹.

With Wegovy, the label says to take the needle off after each shot and store the pen without one attached. If you miss more than two Wegovy doses in a row, your prescriber may restart you lower on the dose ladder to spare your stomach².

The fridge rules favour Wegovy for travel. Once it is in use, a Wegovy pen can stay at room temperature for up to 8 weeks, which covers the whole pen². A Zepbound pen gets up to 30 days unrefrigerated¹.

In Canada, Zepbound comes only as a KwikPen in six strengths, from 2.5 mg to 15 mg per dose³. The single-dose Wegovy pens were approved here but never sold, so the FlexTouch is the version you will get³.

Zepbound vs Wegovy side effects

The side effects are close. Both mainly upset the stomach, most often while the dose is still rising⁴. In SURMOUNT-5, nausea was reported by about 44% of people in each group.

Vomiting was more common on semaglutide (21.3% vs 15.0%), and injection-site redness or itching was more common on tirzepatide (8.6% vs 0.3%)⁷. The full side-effect table sits on our Mounjaro vs Ozempic page.

Both Canadian labels open with the same boxed warning on thyroid C-cell tumours found in rodent studies, and neither drug is for anyone with a personal or family history of medullary thyroid cancer or MEN 2^1,2. The Wegovy label also reports that hair loss was more common in adults who lost 20% or more of their weight than in those who lost less (5.3% against 2.5%)².

Zepbound vs Wegovy cost in Canada

At the starting doses, Zepbound’s estimated cash price begins a little below Wegovy’s. From 7.5 mg up, Zepbound usually costs more per pen, and at 12.5 or 15 mg even Zepbound’s lowest price sits above Wegovy’s highest. These are prices for one pen (four weekly doses), dispensing fee included, before any insurance¹⁰.

Zepbound and Wegovy cash prices in Canada, one 4-week pen

Brand (use in Canada)	Dose	What you get	Cash price	Basis
Wegovy (weight)	any strength	1 pen, 4 weekly doses	$380–507	Audited at Costco, Walmart, London Drugs, Rexall and Shoppers; estimated elsewhere
Zepbound (weight)	2.5 or 5 mg	1 pen, 4 weekly doses	$314–418	Estimated
Zepbound (weight)	7.5 or 10 mg	1 pen, 4 weekly doses	$439–581	Estimated
Zepbound (weight)	12.5 or 15 mg	1 pen, 4 weekly doses	$563–742	Estimated

How to read the table:

• Wegovy is one price at every strength. In this data, a 0.25 mg starter pen costs the same as a 2.4 mg pen, so the first months cost as much as the rest¹⁰.
• Zepbound is priced in three tiers. The 2.5 and 5 mg pens sit in the lowest tier, 7.5 and 10 mg in the middle, and 12.5 and 15 mg at the top¹⁰. If you settle at 5 mg, you stay in the cheapest tier.
• Only the Wegovy row is audited. Its drug price comes from a retail phone audit at five chains in August 2026. Every Zepbound row is modelled from list prices, because no audited Canadian Zepbound price exists yet¹⁰.

Our Zepbound price guide for Canada goes deeper on Zepbound’s list prices and the ways people try to pay less.

Will a drug plan pay for Zepbound or Wegovy?

Probably not a public plan, at least not yet. Canada’s Drug Agency (CDA-AMC) gave each drug a “reimburse with conditions” recommendation, but for different groups of people, and each group mirrors that drug’s strongest evidence^11,12.

• Wegovy, July 2025. The agency’s conditions point to adults with a BMI of 27 or more who already have heart disease, the same kind of people studied in SELECT, and they require a lower price¹¹. Global News reported in December 2025 that Novo Nordisk would not take part in price talks for public plans¹³.
• Zepbound, August 2026. Here the target group is people with prediabetes and a BMI from 27 up, after at least one failed attempt at dieting. Staying covered after the first year would need at least 5% weight loss, Zepbound should not be paid for alongside another GLP-1, and the price has to come down¹².

A recommendation is advice to the provinces, not a listing. If you have prediabetes, Zepbound has the clearer path to public coverage on paper. If you have had a heart attack or stroke, Wegovy is the one the agency had in mind.

Private and workplace plans set their own rules, so check yours before you choose a brand. Our guide to getting a weight-loss injection in Canada lists the questions to ask your insurer.

Is there a generic Zepbound or generic Wegovy?

No, not one you can fill. Sevmia, Apotex’s generic semaglutide with a weight label, got its approval on June 29, 2026, but was still listed as not marketed on November 12, 2026^3,5. Even when it arrives, it comes only as a 1 mg dose pen, below Wegovy’s 2.4 mg maintenance dose³.

The generic semaglutide pens on pharmacy shelves now copy Ozempic, so they carry a diabetes label³. Health Canada’s list of generic submissions under review showed 11 more semaglutide filings and no tirzepatide filing as of September 30, 2026¹⁴. Zepbound has no generic in sight here.

Which one should you ask your prescriber about?

Start with Zepbound if the most weight loss is what you are after and no special condition points elsewhere. Start with Wegovy if your heart, your age or your budget at higher doses changes the picture. Here is how the details sort people:

• You want the biggest average result. Zepbound, based on SURMOUNT-5⁴.
• You have had a heart attack or stroke, or have peripheral artery disease. Wegovy has the heart-outcome trial, the Canadian label and the CDA-AMC criteria on its side^8,2,11.
• You have obesity and moderate to severe sleep apnea. Zepbound is the one labelled for it¹.
• You are 12 to 17. Wegovy is the only choice of the two².
• You have prediabetes and hope for public coverage someday. Zepbound’s CDA-AMC criteria were written for you¹².
• You take the birth control pill or plan a pregnancy soon. Compare the label advice above; the rules are stricter for Zepbound on the pill and longer for Wegovy before conceiving.
• You expect to need a high dose and pay cash. Zepbound at 12.5 or 15 mg costs more per pen than Wegovy at any dose¹⁰.
• You travel a lot or have no fridge at work. A Wegovy pen in use keeps longer at room temperature².

Still torn between the two? Take the one-minute quiz and answer a few questions about your health, your budget and your drug plan. If you want to see how these two rank against every other GLP-1, read our guide to the best GLP-1 for weight loss.

Can you switch from Wegovy to Zepbound?

Yes, with your prescriber’s help. The usual reasons are wanting more weight loss, struggling with side effects or a change in coverage.

Neither Canadian monograph includes a conversion chart from one drug to the other. The Zepbound label calls 2.5 mg the dose “for treatment initiation”¹, so where you restart is your prescriber’s call.

A few ground rules from the labels and the trials:

• Never overlap them. Both labels advise against taking either drug with another GLP-1 medicine^1,2.
• Expect some stomach trouble again. In the head-to-head trial, the gut side effects came mostly during the dose increases⁴.
• Check the birth control rule. If you use the pill, the Zepbound advice about a backup method applies after each step up¹.
• Call your plan first. Coverage for one brand says nothing about the other.

The same applies in reverse. The Wegovy label has no conversion chart either, so your prescriber decides where on its dose ladder you start.

How we compared Zepbound and Wegovy

We read both Canadian product monographs from cover to cover: the Zepbound version authorized June 11, 2026, and the Wegovy version authorized October 2, 2026^1,2. On November 12, 2026, we looked up both brands, their DINs and Sevmia in Health Canada’s drug and approval databases^3,5.

Trial figures on this page come from a journal paper or a monograph, never from a company press release. The prices all come from a single dataset, and each row says whether it was audited or estimated¹⁰.

Nobody on our team gave either drug to anyone. A pharmacist has not checked this page yet, which is why it carries a “Pharmacist review pending” label for now. Our grading method explains how evidence earns a grade, and the full rankings show where tirzepatide and semaglutide sit next to every other weight-loss peptide.

Use this page to prepare for an appointment, not to replace one. Your doctor, nurse practitioner or pharmacist should weigh in before you begin, change or quit either drug.